U.S., Feb. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07380659) titled 'Safety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock' on Jan. 05.
Brief Summary: To study the safety and efficacy of fibroblast activation protein (FAP)-targeted allogeneic immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of acute myocardial infarction with cardiogenic shock and provide a new method for the treatment of acute myocardial infarction with cardiogenic shock.
Study Start Date: Jan. 20
Study Type: INTERVENTIONAL
Condition:
Cardiogenic Shock
Cardiogenic Shock Post Myocardial Infarction
STEMI - ST Elevation Myocardial Infarction
Intervention:
BIOLOGIC...